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ERBB2-, ERBB3- and PIK3CA-mutations (Kamat et al., 2016; McConkey
et al., 2015; Choi et al., 2014). BC patientswith invasive basal tumors ex-
hibit signiﬁcantly lower survival rates compared to patients suffering
from invasive luminal tumors (Choi et al., 2014). This observation is
convincingly proven by Dadhania et al. by analysis of survival rates of
BC patients in several large cohorts (Dadhania et al., 2016).Bladder cancer (BC) is the 4th most common cancer in men and the
11th most common in women (Kamat et al., 2016). The majority of
bladder carcinomas (~90%) are non-invasive papillary tumors that are
treated by transurethral resection followed by intravesical BCG installa-
tions or chemotherapy (Kiselyov et al., 2016). The superﬁcial papillary
tumors rarely progress to invasive carcinomas but they have a high pro-
pensity for recurrence. This necessitates a lifetime of invasive surveil-
lance by repeated cystoscopy.
On the other hand, non-papillary tumors have a high tendency for
aggressive invasive growth and are associatedwith poor 5-year survival
ranging from 30 to 50% (Kiselyov et al., 2016). Current therapeutic op-
tions inmuscle-invasive BC are limited. Apart from cisplatin-based che-
motherapy and cystectomy, only one other treatment (anti-PDL1) has
been approved in the past 30 years. Moreover, reliable biomarkers for
patient stratiﬁcation are not currently available. Ongoing clinical trials
and targeted therapy studies are aiming to appropriately develop
novel treatments and assess the performance of prognostic and predic-
tive biomarkers for patients suffering from invasive BC (Anon, 2014;
Mbeutcha et al., 2016; Knollman et al., 2015).
Invasive BC is heterogeneous at the molecular level and can be
grouped into 2 main subtypes (basal and luminal) with distinct clinical
behaviors and responses to chemotherapy. The basal subtype expresses
a signature similar to an undifferentiated basal layer of normal
urothelium with frequent features of squamous differentiation along
with up-regulation of markers characteristic of epithelial-to-
mesenchymal transition (EMT). They also show overexpression of hyp-
oxia induced factor 1 (HIF-1) and epidermal growth factor receptor
(EGFR) with many of its ligands. The luminal subtype comprises papil-
lary non-invasive tumors and a subset of invasive urothelial cancers.
In the majority of these tumors, the PI-3 kinase/AKT pathway is altered
(McConkey et al., 2015). Luminal tumors expressmarkers characteristic
of intermediate and luminal urothelial differentiation, high levels ofom.2016.08.036.
. This is an open access article underﬁbroblast growth factor receptor-3 (FGFR3) and activating FGFR3-,
A luminal subtype termed “p53-like”, is characterized by high levels
of inﬁltrating stromal cells, particularly cancer-associated ﬁbroblasts.
These tumors are enriched with extracellular matrix (ECM) biomarkers
and are resistant to neoadjuvant cisplatin-based chemotherapy. This
chemoresistance is probably due to the rather “quiescent” state of
those tumors compared to the other subtypes. A similar link between
quiescence and chemoresistance has been observed in luminal breast
cancers which share many features with BC “p53-like” tumors. There
is also a basal aggressive subtype termed “claudin-low” with strong
mesenchymal signature. This subtype is characterized by stem cell-
like properties, down-regulation of claudins 3, 4 and 7 and up-
regulation of EMT markers (Kamat et al., 2016; McConkey et al., 2015;
Damrauer et al., 2014).
Dadhania et al. (Dadhania et al., 2016) report transcriptomics data
that clearly deﬁne the basal and luminal subtypes on three large cohorts
of fresh-frozenBC tissue samples. The authors demonstrate that the “p-53
like” transcriptomic signature is present in a subset of both luminal and
basal tumors. They also show that the “claudin-low” subtype does not ex-
press luminal or basal markers, so they deﬁne it as “double negative”.
Subsequently, the authors established a protocol based on IHC for
easy assignment of BC tumors to thebasal or luminal subtypeusing a co-
hort of formalin-ﬁxed parafﬁn-embedded BC tissue samples. Basal tu-
mors expressed high levels of Keratin 5/6 whereas luminal tumors
were characterized by signiﬁcant GATA3 overexpression. Additionally,
the IHC analysis indicated that the “p53-like” molecular features do
not originate from cancer cells but are due to stromal cells. Therefore
the “p53-like” subtype does not appear to be an “intrinsic” BC subtype.
Further experimental validation by laser capture microdissection and
transcriptomics analysis of the cancer and stromal components of blad-
der sections is necessary in order to conﬁrm this observation.
The simple IHC-based classiﬁcation of BC tumors proposed by
Dadhania et al. (Dadhania et al., 2016) has the potential to assist physi-
cians in identifying patients suffering from highly aggressive basal tu-
mors. Unfortunately, the two biomarkers reported cannot identify
double negative tumors (5% of invasive BC cases) that exhibit poor sur-
vival rates. A subsequent step would be to develop a support-vectorthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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markers for efﬁcient discrimination of double negative tumors.
Preclinical data have demonstrated that basal tumors are sensitive to
EGFR inhibitors. However, EMT as a characteristic of basal tumors con-
fers resistance to EGFR inhibitors in BC cells. Therefore, epigenetic
agents (e.g. histone deacetylase inhibitors) could be used to reverse
EMT and promote sensitivity to EGFR inhibitors in those tumors
(McConkey et al., 2015). Additionally, there aremany clinically available
agents to inhibit HIF-1 pathway in basal tumors (e.g. inhibitors of the
proteasome, mammalian target of rapamycin, vascular endothelial
growth factor receptor-2 (VEGFR-2)). Recently, a combination of VEGF
or VEGFR-2 inhibitors with conventional chemotherapy in patients
with basal tumors yielded satisfactory results (McConkey et al., 2015).
For luminal tumors, small molecule and blocking antibody FGFR in-
hibitors are being evaluated in patients and clinical trials with pan-ERBB
inhibitors are being planned (McConkey et al., 2015).Moreover, there is
evidence that targeting the PI-3 kinase/AKT/mTOR pathway could pro-
duce strong clinical responses in patients with luminal tumors
(Kiselyov et al., 2016; McConkey et al., 2015).
Up-regulation of cytotoxic T-lymphocyte-associated protein 4
(CTLA-4), programmed death-ligand 1 (PD-L1) and programmed cell
death protein 1 (PD-1) in either the tumor itself or the surrounding im-
mune cells, has been associated with BC's ability to escape the cell-
killing effects of treatment (Kamat et al., 2016). Drugs targeting those
molecules have demonstrated greater response rates and better tolerance
than platinum-based chemotherapy. Patientswith luminal “p-53 like” tu-
mors responded better to anti-PD-L1 therapies than basal tumors
(Kamat et al., 2016). As alluded to above, in May 2016, the anti-PD-
L1 drug atezolizumab was approved by the FDA for the treatment
of progressing metastatic BC during or after platinum-based chemo-
therapy, representing theﬁrst drug approval formuscle-invasive bladder
cancer in decades (Kamat et al., 2016; Drake et al., 2016).The data presented by Dadhania et al. (Dadhania et al., 2016) open
the way for efﬁcient stratiﬁcation of BC tumors into luminal and basal
subtypes. The clinical application of theseﬁndings is important since pa-
tients will beneﬁt from recently developed targeted therapies.Disclosure
The author declared no competing interests.References
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